- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00776568
Treatment of Refractory Angina Pectoris by Shock Wave Therapy
Extracorporeal Shock Wave Therapy (ESWT) for the Treatment of Refractory Angina Pectoris
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with advanced CAD frequently have limited symptoms with recurrent angina, angina at low work thresholds, breathlessness, and other debilitating conditions. These patients have often been through several "re-do" coronary bypass procedures and multiple percutaneous coronary interventions.
Surgical and interventional options for these patients typically have been exhausted or will result in only partial revascularization. Therefore, therapy remains limited to the use of multiple anti-anginal medications, reduced activity, exertion, and stress level, and significant alteration and limitation of lifestyle.
The goal of this emerging approach is to therapeutically induce the growth and development of new vasculature in zones of severe ischemia in the myocardium, with the hope that new capillaries and arterioles generated will connect to remnant existing vasculature. These neovessels are viewed to act as collaterals, perfusing ischemic territories unapproachable by macro procedures such as PCI and/or CABG.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Karachi, Pakistan
- Karachi Institute of Heart Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, 18 years or older.
- Diagnosis of chronic stable angina pectoris. Diagnosis is based on medical history, complete physical evaluation, and Exercise Single-Photon Emission Computed Tomography (Exercise SPECT).
- Patient has documented myocardial segments with reversible ischemia and or hibernation.
- Patient is classified as AP CCS of III or IV.
- Patient should be on a stable dosage of medication used to treat angina for at least 6 weeks prior to enrollment.
- Patients demonstrates exercise tolerance time (ETT) duration <10 minutes on a modified Bruce protocol on 2 consecutive tests (tests no less than 24 hours and no more than 2 weeks apart), with the second test within 25% of the first (Patients should not be informed of exercise restrictions required for entry into the study).
- Patient has refused to undergo another angioplasty or CABG.
- Patient has signed an informed consent form.
- Patient's condition should be stable and should have a life expectancy of >12 months.
- Patient's current and past medical condition and status will be assessed using previous medical history, physical evaluation, and the physicians (principle investigator's) medical opinion.
- Newly diagnosed type II diabetes.
Exclusion Criteria:
- Chronic lung disease including emphysema and pulmonary fibrosis.
- Active endocarditis, myocarditis or pericarditis.
- Patient is simultaneously participating in another device or drug study, or has participated in any
- Clinical trial involving an experimental device or drug, including other drugs or devices enhancing cardiac neovascularization, or any ESWT machine for neovascularization of a competitor company within 3 months of entry into the study.
- Patients who are unwilling or unable to cooperate with study procedure.
- Patients who are unwilling to quit smoking during the study procedure (including screening phase)
- Patients who had myocardial infarction (MI) less than 3 months prior to treatment.
- Patients who are diagnosed with a 3rd and 4th degree heart valve disease.
- Patient with intraventricular thrombus.
- Pregnancy.
- Patient with a malignancy in the area of treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
Low intensity shock waves are applied as 300 shocks per visit for 09 visits.
The treatment visit is carried at week 1, 5 and 9.
|
Active Comparator: 2
|
ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Alleviation of anginal symptoms
Time Frame: 06 months
|
06 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change in SPECT in perfusion from baseline to 6 months post-baseline (17 segments model
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Prof. Abdul Samad, MD, Karachi Institute of Heart Diseases
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- URG/UQ/002/01
- ISRCTN68966125
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angina Pectoris
-
University Hospital, AntwerpRecruitingAngina Pectoris, Variant | Angina Pectoris; Spasm-Induced | Angina Pectoris With Normal Coronary ArteriogramBelgium
-
The People's Hospital of Liaoning ProvinceUnknownStable Angina Pectoris | Unstable Angina PectorisChina
-
Society for Advancement of Coronary Intervention...UnknownStable Angina Pectoris | Unstable Angina PectorisJapan
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentNot yet recruitingAngina Pectoris; Angiospastic
-
Region Örebro CountyBiosensors InternationalWithdrawnStable Angina Pectoris | Unstable Angina Pectoris | Myocardial Infacrtion
-
Atlantic Health SystemMallinckrodtTerminatedStable Angina Pectoris | Unstable Angina Pectoris | Silent IschemiaUnited States
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...UnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...UnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe First Affiliated Hospital of Zhejiang Chinese Medical UniversityUnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...Unknown
Clinical Trials on Anti-hypertensive drugs
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...CompletedChronic Kidney Diseases | Blood Pressure | Chronic Kidney Disease Stage 5 | End Stage Renal Disease on Dialysis (Diagnosis)United States
-
UConn HealthNational Institute on Aging (NIA)CompletedCerebrovascular Disease | Hypertension, SystolicUnited States
-
University of OxfordRecruitingCardiovascular Diseases | Vascular Diseases | Cerebrovascular Disorders | HypertensionUnited Kingdom
-
Radboud University Medical CenterDutch Heart FoundationUnknown
-
University of PaviaIRCCS Policlinico S. MatteoUnknown
-
Saint Thomas Hospital, PanamaCompletedHypertension, Pregnancy-InducedPanama
-
Federal University of UberlandiaCompleted
-
University of OxfordNational Institute for Health Research, United KingdomCompletedPre-Eclampsia | Hypertension, Pregnancy-InducedUnited Kingdom
-
The Hong Kong Polytechnic UniversityUnknown
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American...RecruitingHypertension | Chronic Kidney DiseasesUnited States